首页> 外文期刊>Journal of drug targeting >Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery.
【24h】

Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery.

机译:粘膜粘附性多囊脂质体作为经粘膜胰岛素递送的有效载体。

获取原文
获取原文并翻译 | 示例
           

摘要

Considering limitations of conventional insulin therapies, the present study characterizes usefulness of novel mucoadhesive multivesicular liposomes as a mucoadhesive sustained release carrier of insulin via nasal and ocular routes, thus attempts to develop non-invasive carrier system for the controlled release of bioactives. Multivesicular liposomes (MVLs) of 26-34 microm were prepared with a high protein loading (58-62%) and were coated with chitosan and carbopol. These mucoadhesive carriers were characterized by zeta potential studies, in vitro mucoadhesion test and insulin protective ability against nasal aminopeptidase. In vitro, mucoadhesive carriers released insulin for a period of 7-9 days compared to 24 h of conventional liposomes. After intranasal administration to STZ induced diabetic rats, the mucoadhesive MVLs (chitosan coated MVLs) effectively reduced plasma glucose level up to 2 days (35% reduction), compared to non-coated MVLs (32% at 12 h) and conventional liposomes (34% at 8 h). Although the differences are statistically insignificant, chitosan coated formulation has shown a better hypoglycemic profile as the effects were prolonged compared to carbopol coated formulation. When compared to ocular route, chitosan formulation after nasal administration has shown better therapeutic profile as the hypoglycemic effects were prolonged until 72 h. The effectiveness of this chitosan coated MVLs was further demonstrated by the significant quantities of ELISA detectable insulin levels after nasal (334.6 microIu/ml) and ocular (186.3 microIu/ml) administration. These results demonstrate that mucoadhesive carrier is a viable option for a sustained release transmucosal insulin carrier, and open an avenue to develop a non-invasive carrier platform for the controlled release of bioactives.
机译:考虑到常规胰岛素疗法的局限性,本研究将新型粘膜粘附性多囊脂质体作为通过鼻和眼途径的胰岛素的粘膜​​粘附性缓释载体的有用性进行了表征,因此试图开发用于控制释放生物活性物质的非侵入性载体系统。制备具有高蛋白质载量(58-62%)的26-34微米的多囊脂质体(MVL),并用壳聚糖和卡波普包被。这些粘膜粘附载体的特征在于zeta电位研究,体外粘膜粘附试验和胰岛素对鼻氨基肽酶的保护能力。在体外,与常规脂质体24小时相比,粘膜粘附性载体释放胰岛素的时间为7-9天。经鼻内给药STZ诱导的糖尿病大鼠后,与未包被的MVL(在12 h时为32%)和常规脂质体相比,粘膜粘附的MVL(壳聚糖包被的MVL)可有效降低血浆葡萄糖水平长达2天(减少35%)。 %在8小时)。尽管差异在统计学上无关紧要,但是与卡波普包衣的制剂相比,壳聚糖包衣的制剂具有更好的降血糖作用,因为其作用被延长。与眼部途径相比,经鼻给药后的壳聚糖制剂具有更好的治疗效果,因为降糖作用可延长至72小时。鼻腔给药(334.6 microIu / ml)和眼内给药(186.3 microIu / ml)后,ELISA检测到的胰岛素水平显着提高,进一步证明了这种壳聚​​糖包被的MVL的有效性。这些结果表明,粘膜粘附载体对于持续释放的透粘膜胰岛素载体是可行的选择,并为开发用于控制释放生物活性物质的非侵入性载体平台开辟了道路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号